PT2849798T - Composições de complexo quelato de oligonucleótidos-polipéptido e métodos - Google Patents

Composições de complexo quelato de oligonucleótidos-polipéptido e métodos

Info

Publication number
PT2849798T
PT2849798T PT137916185T PT13791618T PT2849798T PT 2849798 T PT2849798 T PT 2849798T PT 137916185 T PT137916185 T PT 137916185T PT 13791618 T PT13791618 T PT 13791618T PT 2849798 T PT2849798 T PT 2849798T
Authority
PT
Portugal
Prior art keywords
methods
chelate complex
polypeptide compositions
oligonucleotide chelate
oligonucleotide
Prior art date
Application number
PT137916185T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49581470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2849798(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of PT2849798T publication Critical patent/PT2849798T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
PT137916185T 2012-05-18 2013-05-17 Composições de complexo quelato de oligonucleótidos-polipéptido e métodos PT2849798T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261648711P 2012-05-18 2012-05-18
US201261695035P 2012-08-30 2012-08-30

Publications (1)

Publication Number Publication Date
PT2849798T true PT2849798T (pt) 2021-05-18

Family

ID=49581470

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137916185T PT2849798T (pt) 2012-05-18 2013-05-17 Composições de complexo quelato de oligonucleótidos-polipéptido e métodos

Country Status (34)

Country Link
US (1) US9492506B2 (enExample)
EP (1) EP2849798B1 (enExample)
JP (1) JP2015517504A (enExample)
KR (1) KR102068109B1 (enExample)
CN (1) CN104349793B (enExample)
AU (1) AU2013262416B2 (enExample)
BR (1) BR112014028654A2 (enExample)
CA (1) CA2873529C (enExample)
CL (1) CL2014003134A1 (enExample)
CO (1) CO7131387A2 (enExample)
CR (1) CR20140527A (enExample)
CY (1) CY1124345T1 (enExample)
DK (1) DK2849798T3 (enExample)
DO (1) DOP2014000264A (enExample)
EA (1) EA035967B1 (enExample)
EC (1) ECSP14027694A (enExample)
ES (1) ES2873844T3 (enExample)
HR (1) HRP20210840T1 (enExample)
HU (1) HUE054875T2 (enExample)
IL (1) IL235548B (enExample)
LT (1) LT2849798T (enExample)
MX (1) MX346239B (enExample)
MY (1) MY168778A (enExample)
NZ (1) NZ703095A (enExample)
PH (1) PH12014502551B1 (enExample)
PL (1) PL2849798T3 (enExample)
PT (1) PT2849798T (enExample)
RS (1) RS62030B1 (enExample)
SG (1) SG11201407599SA (enExample)
SI (1) SI2849798T1 (enExample)
SM (1) SMT202100319T1 (enExample)
TW (1) TWI635864B (enExample)
WO (1) WO2013170386A1 (enExample)
ZA (1) ZA201408674B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5646320B2 (ja) 2007-05-11 2014-12-24 アダイニクス， インコーポレイテッド 遺伝子発現と疼痛
RU2668136C2 (ru) 2012-05-10 2018-09-26 Эйдинкс, Инк. Композиции для доставки активных ингредиентов
CN104837501B (zh) 2012-08-30 2018-11-02 里普利科股份有限公司 治疗乙型肝炎及丁型肝炎感染的方法
KR20170029577A (ko) * 2014-07-10 2017-03-15 레플리코르 인코포레이티드 B형 간염 및 d형 간염 바이러스 감염의 치료 방법
CN106661578B (zh) 2014-08-15 2020-08-04 埃迪恩克斯股份有限公司 用于疼痛治疗的寡核苷酸诱饵
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20200147124A1 (en) * 2018-11-08 2020-05-14 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
EP4728073A1 (en) * 2023-06-16 2026-04-22 Ractigen Therapeutics Oligonucleotide formulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2769114B2 (ja) * 1993-10-29 1998-06-25 サイクローン・ファーマシューティカルズ ミニマルｂ型肝炎感染症治療用医薬組成物
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
EA008940B1 (ru) * 2002-09-13 2007-10-26 Репликор, Инк. Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей
CN1997666A (zh) * 2003-02-26 2007-07-11 印特缪恩股份有限公司 聚乙二醇修饰的干扰素组合物及其使用方法
CN1893978A (zh) * 2003-10-27 2007-01-10 沃泰克斯药物股份有限公司 用于hcv治疗的组合
WO2006042418A1 (en) * 2004-10-19 2006-04-27 Replicor Inc. Antiviral oligonucleotides
WO2007022642A2 (en) * 2005-08-25 2007-03-01 Replicor Inc. Anti-inflammatory molecules and their uses
EP1928498A4 (en) * 2005-09-29 2009-11-11 Cell Biosciences Inc S METHOD FOR THE TREATMENT OF T-CELL DISORDERS WITH TISF
US20090215873A1 (en) * 2005-09-29 2009-08-27 Andrew Vaillant Therapeutic Molecules and their Uses
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
NZ585784A (en) * 2007-12-13 2012-09-28 Alnylam Pharmaceuticals Inc siRNAs for the treatment and prevention of respiratory syncytial virus (RSV) infection
EP2268811A1 (en) * 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
KR101704988B1 (ko) * 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
ES2651308T3 (es) * 2009-10-16 2018-01-25 Glaxo Group Limited Inhibidores antisentido de HBV
JP5775581B2 (ja) * 2010-08-20 2015-09-09 レプリコール インコーポレーティッド オリゴヌクレオチドキレート錯体
CN104837501B (zh) 2012-08-30 2018-11-02 里普利科股份有限公司 治疗乙型肝炎及丁型肝炎感染的方法

Also Published As

Publication number Publication date
LT2849798T (lt) 2021-08-10
EA035967B1 (ru) 2020-09-07
SG11201407599SA (en) 2014-12-30
MX2014014021A (es) 2015-02-10
WO2013170386A1 (en) 2013-11-21
PL2849798T3 (pl) 2021-10-18
AU2013262416B2 (en) 2017-05-11
KR102068109B1 (ko) 2020-01-21
EA201401278A1 (ru) 2015-04-30
RS62030B1 (sr) 2021-07-30
IL235548A0 (en) 2015-01-29
CA2873529C (en) 2020-08-18
HK1204279A1 (en) 2015-11-13
SMT202100319T1 (it) 2021-09-14
IL235548B (en) 2019-07-31
MY168778A (en) 2018-12-04
US9492506B2 (en) 2016-11-15
ECSP14027694A (es) 2015-12-31
HUE054875T2 (hu) 2021-10-28
SI2849798T1 (sl) 2021-08-31
KR20150013309A (ko) 2015-02-04
DOP2014000264A (es) 2015-01-31
CR20140527A (es) 2014-12-15
CA2873529A1 (en) 2013-11-21
EP2849798B1 (en) 2021-04-07
CL2014003134A1 (es) 2015-02-13
JP2015517504A (ja) 2015-06-22
NZ703095A (en) 2016-07-29
BR112014028654A2 (pt) 2017-10-10
EP2849798A1 (en) 2015-03-25
AU2013262416A1 (en) 2014-12-18
TW201408308A (zh) 2014-03-01
PH12014502551B1 (en) 2019-10-11
DK2849798T3 (da) 2021-05-31
TWI635864B (zh) 2018-09-21
CN104349793A (zh) 2015-02-11
HRP20210840T1 (hr) 2021-08-06
MX346239B (es) 2017-03-13
CY1124345T1 (el) 2022-07-22
EP2849798A4 (en) 2016-03-09
US20130309201A1 (en) 2013-11-21
CO7131387A2 (es) 2014-12-01
ZA201408674B (en) 2016-01-27
PH12014502551A1 (en) 2015-01-21
ES2873844T3 (es) 2021-11-04
CN104349793B (zh) 2017-11-10

Similar Documents

Publication Publication Date Title
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
EP2852602A4 (en) COMPOSITIONS AND METHODS FOR CONJUGATING OLIGONUCLEOTIDES
ZA201408082B (en) Oligonucleotide chelate complex methods
IL233649A0 (en) Preparations derived from chitosan
ZA201408674B (en) Oligonucleotide chelate complex-polypeptide compositions and methods
GB201322986D0 (en) Compositions
IL234695B (en) Antigen compositions and methods
ZA201503157B (en) Compositions
GB201209244D0 (en) Compositions
GB201315350D0 (en) Methods and compositions
EP2874641A4 (en) COMPOSITIONS INCREASING THE GLUTATHION RATE AND USES THEREOF
GB201210800D0 (en) Compositions
GB201315347D0 (en) Methods and compositions
ZA201308892B (en) Compositions and methods
ZA201503062B (en) Compositions
GB201220068D0 (en) Compositions
ZA201502542B (en) Compositions
GB201219973D0 (en) Compositions
GB201219962D0 (en) Compositions
GB201219980D0 (en) Compositions
TWI561248B (en) Peracid-generating compositions
EP2926813A4 (en) METFORMIN-Orlistat COMPOSITIONS
GB201116340D0 (en) Compositions and methods
GB201223148D0 (en) Compositions
GB201222702D0 (en) Compositions